Pirtobrutinib
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 163 publications
Bridging the Gap: Pirtobrutinib for Treatment-Naïve Chronic Lymphatic Leukemia.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 20, 2026
Shifting clones: CLL evolution under pirtobrutinib treatment.
Journal: Blood
Published: January 01, 2026
New BTK Inhibitors May Combat Resistance in CLL.
Journal: Cancer discovery
Published: December 22, 2025
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 09, 2025
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 07, 2025
A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321.
Journal: British journal of haematology
Published: November 13, 2025
The Evolving Therapeutic Landscape of Richter Transformation.
Journal: Current hematologic malignancy reports
Published: November 02, 2025
The Development of Novel Therapies for Chronic Lymphocytic Leukaemia in the Era of Targeted Drugs.
Journal: Journal of clinical medicine
Published: October 27, 2025
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; durvalumab, cemiplimab, zongertinib, and taletrectinib for lung cancer, pirtobrutinib and atezolizumab for lymphoma, durvalumab for bladder cancer, panitumumab plus sotorasib for colorectal cancer, and vorasidenib for glioma.
Journal: International journal of clinical oncology
Published: October 25, 2025
First Fluorescence Method for Native Quantification of Pirtobrutinib Used for Treatment of Cancer in its Market Form and Biological Fluids; Application of Greenness.
Journal: Journal of fluorescence
Published: October 05, 2025
Pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.
Journal: Future oncology (London, England)
Published: October 03, 2025
Last Updated: 02/24/2026